EGFR and colorectal carcinoma: Although the incidence of innate MET amplification in CRC patients is only 2%–4% [129, 130], as MET is similar to HER2, some CRCs harbor acquired MET amplification during the process of anti-EGFR therapy [128, 131, 132].